Use of Proceeds from New Share Issuance for R&D and Increased Personnel Costs
First written in FY2022-Q2. 1 of 3 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2022.
47 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「The issuance of new shares increased capital and capital surplus by ¥206.469 million each.」
The annual report reconfirmed the completion of the public offering and third-party allotment accompanying the listing. It did not describe the planned use of proceeds for R&D and increased personnel costs as actual expenditure. - FY2022-Q3AdvancedAnnual report
「The issuance of new shares in connection with the listing of the Company's common shares on the Tokyo Stock Exchange Growth Market increased capital and capital reserve by ¥156.400 million each. The issuance of new shares through a third-party allotment in connection with the over-allotment sale resolved at the board meeting held on 24 June 2022 was paid in on 29 August 2022, increasing capital and capital reserve by ¥50.029 million each.」
In addition to the public offering accompanying the listing, payment for the third-party allotment was completed on 29 August, increasing capital and capital reserve. The use of proceeds for R&D and increased personnel costs was not reiterated in this filing, but a concrete funding milestone was added. - FY2022-Q2First statedAnnual report
「The proceeds from the public offering of new shares, together with the proceeds from the third-party allotment of new shares, are scheduled to be used for R&D expenses and increased personnel costs.」
The Company planned to use the ¥312,800,000 proceeds from the public offering and ¥100,059,200 from the third-party allotment for R&D expenses and increased personnel costs. The public-offering payment was completed on 27 July 2022, and payment for the third-party allotment was scheduled for 29 August 2022.